Urigen

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Urigen sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials none currently recruiting 1 completed early-phase tilt upper quartile by trial count

Urigen: 3 sponsored US clinical trials, none currently recruiting.

Urigen sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bladder Diseases, with 1 trials.

Upper-quartile sponsor footprint

Urigen sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

3 total, page 1 of 1

TERMINATED Phase 2

Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

NCT02591199
TERMINATED Phase 2

Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis

NCT00517868
COMPLETED Phase 2

Study of U101 for Bladder Pain and/or Urgency

NCT00256542

Phase Distribution

PhaseTrial count
Phase 2 3

Therapeutic Areas

Bladder Diseases 1
Interstitial Cystitis 1
Pelvic Pain 1

How the Urigen early-phase archive is shaped

3 indexed studies, none listed as recruiting (0% open); 1 completed (33%).

Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).

Top condition: Bladder Diseases (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Urigen: archived-pipeline peers nationwide

Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Urigen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Urigen10xBio22nd Century GroupAA SecordAAADRS Clinical Research Center23andMe3-C Institute for Social Development3 Waves Wellness3EO Health
Urigen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Urigen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Urigen page

3 registered trials is a research-attention snapshot, not an endorsement of Urigen or any single study.

  • None of Urigen's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Bladder Diseases is the condition Urigen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bladder Diseases trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Urigen pipeline card: 3 registered trials from official public datasets.Report a data error.